MOH (Israel)

The Israel Ministry of Health (MoH) serves as the national regulatory authority across the full lifecycle of human health products. Its mandate spans human medicines, vaccines, biologicals and biosimilars, advanced therapy medicinal products, medical devices, in vitro diagnostics, cosmetics, and dietary supplements. It also regulates clinical trials, pharmacy practice, controlled substances, and public health surveillance, supported by central laboratories and specialized units.

Operationally, the MoH works through domain divisions that include the Pharmaceutical Administration for medicines and biologics oversight, the Institute for Standardization and Control of Pharmaceuticals for laboratory testing and batch release activities, the Medical Devices and Accessories Division (AMAR) for device and IVD market authorizations, and a national Pharmacovigilance Centre for safety data collection and signal management. Public Health Services and the National Food Service provide additional risk management and sanitary controls for overlapping categories and distribution chains.

The MoH’s authority applies across Israel’s administered territory and supply chain nodes, including importation, wholesale distribution, retail pharmacy, and hospital use. Manufacturers, authorization holders, local representatives, importers, and distributors are expected to maintain documented responsibilities for product quality, safety, and performance, and to make records readily available for inspection or post‑market action.

In practice, Israel recognizes and leverages international norms to enable predictable reviews, while preserving national decision‑making. This means three things for compliance teams: adopt recognized international formats and standards, plan for Israel‑specific evidence and labeling, and maintain an inspection‑ready quality system that substantiates claims from development through routine commercial supply.

Israel’s medicines and devices oversight is anchored in national laws and ministerial regulations that codify authorization, manufacturing, importation, distribution, and market surveillance. For medicinal products, the Pharmacists Ordinance (New Version) 1981 provides the core statutory basis for product registration, pharmacy conduct, and sanctions. Subsequent ministerial regulations and circulars operationalize dossier content, advertising controls, storage and distribution standards, and pharmacovigilance obligations.

Within the Ministry, the Pharmaceutical Administration manages medicinal product licensing and lifecycle changes, while the Institute for Standardization and Control of Pharmaceuticals conducts analytical testing, standardization, and investigations of suspect or nonconforming lots. The Pharmacovigilance Centre coordinates safety reporting, risk management plans, and signals handling, and may mandate label changes, targeted communications, or product withdrawals.

For medical devices and IVDs, the AMAR division operates the device registry, classification policy, and device vigilance. AMAR evaluates conformity evidence, quality system credentials, and labeling for market authorization, and it monitors post‑market performance through incident reports and field actions. Public Health Services provides cross‑cutting authority over sanitary measures and outbreak‑linked responses when products intersect with public health risk.

This institutional model expresses a predictable pattern: statutory requirements define obligations, ministerial regulations specify how to meet them, and specialized MoH units evaluate, test, authorize, and enforce. Alignment with ICH guidelines for medicinal products, ISO 13485‑based device quality systems, and internationally harmonized vigilance processes reflects Israel’s intent to integrate with global regulatory science while retaining national controls that address local risk, language, and distribution realities.

Israel’s authorization routes mirror international best practice while retaining local thresholds for evidence and labeling. Medicine and biological dossiers are expected in ICH CTD structure with robust quality, non‑clinical, and clinical data. The MoH evaluates benefit‑risk on Israeli labeling, intended use, and population relevance, and can draw on reliable foreign assessments as supportive evidence when justified.

For medical devices and IVDs, AMAR applies risk‑based classification comparable to global models. Higher classes require proof of conformity under a certified quality management system and clinical evidence proportionate to risk. Imported products often rely on credible foreign certifications or approvals as part of the file, but AMAR’s decision remains independent and may request local clarifications, post‑market commitments, or labeling adaptations.

Cosmetics and dietary supplements are subject to distinct product definitions, notification or registration expectations, and labeling standards. Claims language, composition constraints, and safety substantiation should be resolved early to avoid reclassification risks. Planning across development, evidence collection, and dossier authoring benefits from structured stage‑gates and clear change controls. Teams building Israel submissions in parallel with other markets should coordinate classification and claims strategies to reduce divergence and rework.

Device and IVD developers should align early milestones and clinical readiness with AMAR expectations while keeping global plans coherent. For broader program planning and gap checks tailored to Israel, see Israel MoH supplement and device readiness and lifecycle checkpoints in medical device development phases.

Clinical trials of medicinal products conducted in Israel are expected to adhere to ICH GCP principles and to operate under ethics committee oversight recognized by the MoH. Sponsors must ensure protocol feasibility, informed consent in a language the subject understands, appropriate safety monitoring, and timely reporting of serious adverse events. Importation, labeling, and accountability of investigational products are subject to specific controls that should be planned at site activation.

Device and IVD clinical investigations follow a risk‑based approach aligned with international norms, with proportionate clinical evidence required for higher‑risk technologies and novel indications. ISO 14155 provides the operative framework for planning, conduct, monitoring, and reporting of device investigations. Human subject protection, data integrity, and device accountability are central to approvals and site inspections.

Israel’s oversight model supports multicenter and multinational programs. Well‑constructed foreign clinical evidence may be bridged to the Israeli population when justified, but the MoH may still require local user validation or additional post‑market commitments if there are language, practice, or environmental differences that could affect safety or performance. Early dialogue with investigators and local representatives helps adapt recruitment strategies, endpoints, and logistics to national expectations.

Manufacturers supplying Israel must maintain a quality system capable of ensuring consistent product quality and safety. For medicines and biologicals, expectations align with EU GMP structure, with ICH Q‑series concepts embedded in pharmaceutical quality system design, risk management, and lifecycle control. For devices and IVDs, a certified ISO 13485 quality management system is the prevailing baseline, including design controls, production controls, and post‑market processes.

Distribution practices must assure integrity from importation to point of care. Temperature control, security, segregation, and reconciliation are core to GDP compliance. Data integrity principles apply across electronic and paper systems. Where electronic records and signatures are used, systems should demonstrate validated fitness, secure user management, audit trails, record retention, and reliable backup and recovery that withstand inspector scrutiny.

Inspection teams expect to see that documented procedures match actual practice, that training is demonstrably effective, and that deviations drive timely root cause analysis and corrective actions. Suppliers providing critical materials or services must be qualified and periodically re‑assessed. Change control should be risk‑based, with clear impact assessment on Israel‑specific registrations and labeling.

• Show objective evidence of risk management integration across development, manufacturing, and post‑market controls.
• Demonstrate validated electronic systems aligned to 21 CFR Part 11 style controls for data integrity expectations.
• Maintain a living pharmaceutical quality system or device QMS with management review and effectiveness checks.
• Present end‑to‑end batch, lot, and device history records that are contemporaneous, complete, and retrievable.
• Substantiate supplier qualification with audits, technical agreements, and quality‑relevant performance metrics.

Post‑market surveillance is a central MoH expectation. For medicinal products, the Pharmacovigilance Centre coordinates collection and analysis of adverse event reports, periodic safety update reporting, signal detection, and implementation of risk minimization measures. The authorization holder must maintain a qualified person responsible for vigilance, a safety system master file, and procedures for rapid escalation of significant findings.

For medical devices and IVDs, AMAR requires incident reporting, trend analysis where appropriate, and robust corrective and preventive actions. Field safety corrective actions and field safety notices must be executed swiftly, with clear scope, traceable distribution lists, and communications tailored to the Israeli market. Complaint handling should be linked to risk management and clinical evaluation updates, ensuring that new hazards or failure modes are addressed.

Where supply chain corrections are necessary, effective lot or device identification is essential. Many organizations adopt globally harmonized identifiers and barcodes to strengthen distribution visibility and recall precision. Israel‑specific recall classifications and reporting channels apply, and firms should rehearse end‑to‑end execution, from internal escalation to notifying the MoH and informing customers. Strong traceability enables rapid containment and provides the documentary evidence inspectors expect during follow‑up reviews.

Sponsors should proactively analyze safety data unique to Israeli practice, language, and environmental conditions. Patterns that seem benign in pooled global data can become clinically meaningful in specific subpopulations or care pathways. Early signal investigation, transparent communication with the MoH, and measured risk minimization actions preserve benefit‑risk balance and public health.

Labeling and patient information must reflect authorized terms of use and be understandable to intended users in Israel. Medicine labels and patient leaflets are expected in the national language for patient‑facing content, with technical elements harmonized to international nomenclatures where applicable. Device and IVD labels and instructions for use must match the authorized indications, contraindications, warnings, and essential performance characteristics.

For devices, human factors and usability principles must be translated into labeling and design features that reduce use error in real‑world settings. Clear, testable instructions, warnings that address credible risks, and symbols consistent with international standards support safe use. The MoH may scrutinize labeling for consistency with the technical file and clinical evaluation, particularly when intended users include laypersons or when environmental conditions differ from primary reference markets.

Product identification and distribution marking should enable accurate stock rotation, complaint triage, and recalls. Many firms adopt GS1‑based device identifiers and global trade item numbers to align with hospital inventory systems and wholesalers. Promotional materials must conform to the approved labeling and avoid overstating benefit, under‑representing risk, or implying unapproved indications.

Israel aligns many technical expectations with globally accepted frameworks. ICH guidelines shape pharmaceutical quality, non‑clinical, and clinical evidence; ISO 13485 anchors device quality systems; and EU GMP structure informs manufacturing and inspection programs. For devices and IVDs, credible foreign certifications and approvals can support AMAR assessments, but they do not substitute for Israel‑specific review or labeling reconciliation.

Reliance pathways can shorten review when the foreign reference assessment is robust, the authorized indication and dosing or intended use align with Israeli clinical practice, and the submission convincingly bridges any contextual differences. Where supply chains intersect with global anti‑falsification and serialization practices, firms often adopt compatible controls to ease distribution assurance, even when national rules differ from the EU’s falsified medicines directive.

Adjacent regulators such as the EMA, FDA, and other mature authorities provide scientific opinions, guidance, and classifications that Israel may consider, particularly for complex biologicals, advanced therapies, and novel devices. However, applicants should not assume equivalence of categories, evidence thresholds, or risk minimization measures. Where in doubt, seek early clarification through your local representative and align dossier structure, labeling, and risk plans to Israeli expectations.

• Assuming CE or other foreign certification guarantees AMAR registration without local review steps.
• Reusing global labeling without adapting language, cultural context, or healthcare setting nuances.
• Underestimating the need to justify reliance and to bridge foreign clinical or performance data.
• Treating post‑market safety reporting timelines as identical to other jurisdictions.
• Omitting change control impact assessments on Israeli licenses and published materials.

V5 Ultimate operationalizes Israel MoH compliance by unifying product data, quality records, and regulatory evidence in one validated environment. Teams author CTD modules, device technical files, and labeling components with controlled templates, traceable references, and automated audit trails. Cross‑functional workflows align development, manufacturing, and vigilance, ensuring that every claim is linked to test methods, clinical outputs, or risk controls.

During registration, V5 manages structured requirements, versioned documents, and change histories, so you can demonstrate coherence between labeling, risk files, and clinical or performance evaluations. Post‑market, integrated complaints, CAPA, and change control workflows maintain continuous compliance and make inspection‑readiness routine rather than episodic. Field actions are executed with precise targeting using robust lot and device history data.

For inspections and authority questions, V5 provides one‑click retrieval of approval‑ready evidence. Authorization holders and local representatives coordinate seamlessly with controlled access, while suppliers are qualified and re‑assessed through transparent scorecards and agreements. The result is faster, cleaner MoH submissions and a lifecycle system that withstands scrutiny under Israel’s expectations and international benchmarks.